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A 2006 report from the US Institute of Medicine estimates that
over 1.5 million preventable adverse drug events (ADEs) occur
each year in America [1]. Preventable ADEs include situations
where a patient is harmed because a clinician fails to avoid, or
properly manage, an interacting drug combination. Multiple stud-
ies indicate that these drug–drug interactions DDIs are a signiﬁcant
source of preventable ADEs [2,3].
Factors contributing to the occurrence of preventable DDIs in-
clude a lack of knowledge of the patient’s concurrent medications
and inaccurate or inadequate knowledge of drug interactions by
health care providers [4,5]. Information technology, especially
electronic prescribing systems with clinical decision support fea-
tures, can help address each of these factors to varying degrees
and there is currently a great deal of interest from both govern-
ment and private organizations in expanding the use of informa-
tion technology during medication prescribing and dispensing
[1,6]. Unfortunately, studies have found the DDI components of a
wide variety of clinical decision-support tools to be sub-optimal
in both the accuracy of their predictions and the timeliness of their
knowledge [7–9].ll rights reserved.
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edu (R. Boyce).What all of the systems in these studies have in common is that
they rely upon some representation of drug knowledge to infer
DDIs; what we refer to in this paper as a ‘‘Drug-Interaction Knowl-
edge Base” (KB). Currently, a handful of large drug information dat-
abases are used as drug-interaction KBs in a large range of drug
interaction alerting products and electronic prescribing tools [6].
The basic service most drug-interaction KBs provide is to catalog
drug pairs found to interact in clinical trials or reported as such
in clinician-submitted case reports. One major limitation of this
approach is that it constrains drug-interaction KBs, and the tools
that utilize them, to covering only interacting drug pairs that KB
maintainers ﬁnd in the literature and think important to include.
Clinicians often must infer the potential risk of an adverse event
between medication combinations that have not been studied to-
gether in a clinical trial [5]. Systems that only catalog DDI studies
involving drug pairs can offer little or no support in these
situations.
Some contemporary drug interaction KBs supplement their DDI
knowledge by generalizing interactions involving some drug to all
other drugs within its therapeutic class [10]. While clinically rele-
vant class-based interactions exist (for example, the SSRIs and
NSAIDs), this approach has been criticized for leading to some
DDI predictions that are either false or are likely to have little clin-
ical relevance [11,12]. The main reason class-based prediction can
lead to false alerts is because drugs within a therapeutic class do
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predictions can have a negative effect on electronic prescribing
systems by triggering false or irrelevant DDI alerts that can mark-
edly impede the work-ﬂow of care providers [13]. A high rate of
irrelevant alerting is a potential barrier to widespread adoption
of Computerized Physician Order Entry systems with clinical deci-
sion support [14] and stands as a major obstacle to improving pa-
tient safety.
Part of pre-clinical drug development is the use of mechanism-
based DDI prediction to predict interactions between a new drug
candidate and drugs currently on the market [15]. The same
knowledge that is useful for predicting DDIs in the premarket set-
ting can help clinicians in the post-market setting assess the possi-
bility of a DDI occurring between two drugs that have never been
studied together in clinical trials [11]. However, little research has
been done on how to best represent and synthesize drug-mecha-
nism knowledge to support clinical decision making. Our research
attempts to ﬁll this knowledge gap by focusing on how to best uti-
lize drug-mechanism knowledge to help drug-interaction KBs ex-
pand their coverage beyond what has been tested in clinical
trials while avoiding prediction errors that occur when individual
drug differences are not recognized.
A pilot experiment that we conducted helped identify three ma-
jor challenges to representing drug-mechanism knowledge [16].
First, there is often considerable uncertainty behind claims about
a drug’s properties and this uncertainty affects the conﬁdence that
someone knowledgeable about drugs places on mechanism-based
DDI predictions. Another challenge is that mechanism knowledge
is sometimes missing; a fact that can make it difﬁcult to assess
the validity of some claims about a drug’s mechanisms. Finally,
mechanism knowledge is dynamic and any repository for drug-
mechanism knowledge is faced with the non-trivial task of staying
up to date with science’s rapid advances.
We have previously reported on the design and implementation
of a novel knowledge-representation approach that we hypothe-
sized could overcome these challenges [17]. The approach was
implemented in a new system called the Drug-Interaction Knowl-
edge Base (DIKB); a system that enables knowledge-base curators
to link each assertion about a drug property to both supporting
and refuting evidence. DIKB maintainers place evidence for, or
against, each assertion about a drug’s mechanistic properties in
an evidence-base that is kept current through an editorial board ap-
proach. Maintainers attach to each evidence item entered into the
evidence base a label describing its source and study type. Users of
the system can deﬁne speciﬁc belief criteria for each assertion in
the evidence-base using combinations of these evidence-type la-
bels. The system has a separate knowledge-base that contains only
those assertions in the evidence-base that meet belief criteria. The
DIKB’s reasoning system uses assertions in this knowledge-base
and so only makes DDI predictions using those facts considered
current by the system’s maintainers and believable by users.
An intriguing feature of this evidential approach to knowledge
representation is that the system can provide customized views
of a comprehensive body of drug-mechanism knowledge to expert
users who have differing opinions about what combination of evi-
dence justiﬁes belief in a biomedical assertion. Another intriguing
feature is that researchers can test the empirical prediction accu-
racy of a rule-based theory using many sub-sets of a given body
of evidence. The results of such tests can suggest which combina-
tion of evidence enables the theory to make the most optimal set of
predictions in terms of accuracy and coverage of a validation set.
We have found this feature useful for integrating basic science
and clinical research for the purpose of predicting DDIs and discuss
it in more detail in part II of this two-paper series.
A key component of the DIKB is a new evidence taxonomy that,
when combined with a set of inclusion criteria, enables drug ex-perts to specify what their conﬁdence in a drug mechanism asser-
tion would be if it were supported by a speciﬁc set of evidence. The
primary focus of this paper is the design and application of the new
evidence taxonomy. The next section summarizes the require-
ments that the new taxonomy was designed to meet and contrasts
them with other biomedical evidence taxonomies. The section
after presents the current version of the taxonomy and details on
its implementation. Then follows a discussion of our experience
applying the taxonomy to representing drug-mechanism evidence
for 16 active pharmaceutical ingredients including six members of
the HMG-CoA-reductase inhibitor family (statins). This discussion
includes mention of extensions to our previously reported work
on the DIKB’s evidence model [17] including a new algorithm that
the DIKB uses to identify patterns of evidence support that are
indicative of fallacious reasoning by the evidence-base curators.
2. Considerations for an evidence taxonomy oriented toward
conﬁdence assignment
The DIKB’s method for modeling and computing with evidence
depends on an evidence taxonomy oriented toward conﬁdence
assignment. The evidence taxonomy must have sufﬁcient coverage
of all the kinds of evidence that might be relevant including vari-
ous kinds of experiments, clinical trials, observation-based reports,
and statements in product labeling or other resources. Another
important requirement for the taxonomy is that users must be able
to assess their conﬁdence in each type either by itself or in combi-
nation with other types. Only a handful of biomedical informatics
systems exist that attempt to label or categorize evidence; these
include the PharmGKB’s categories of pharmacogenetics evidence
[18], Medical Subject Headings’ Publication Types [19], Gene Ontol-
ogy’s evidence codes [20], and Pathway Tools’ evidence ontology
[21]. The next few sections summarize these biomedical evidence
taxonomies and contrast them with the DIKB’s requirements.
2.1. PharmGKB’s ‘‘categories of pharmacogenetics evidence”
The PharmGKB is a Web-based knowledge repository for phar-
macogenetics and pharmacogenomics research. Scientists upload
into the system data supporting phenotype relationships among
drugs, diseases, and genes. All data in the PharmGKB is tagged with
labels from one or more of ﬁve non-hierarchical categories called
categories of pharmacogenetics evidence [18]. The categories of phar-
macogenetics evidence are different from the DIKB’s evidence types
because the latter represent speciﬁc sources of scientiﬁc inference
such as experiments and clinical trials while the former are de-
signed to differentiate the various kinds pharmacogenetic gene-
drug ﬁndings by the speciﬁc phenotypes they cover (e.g. clinical,
pharmacokinetic, pharmacodynamic, genetic, etc.). In other words,
the categories are oriented toward data integration rather than con-
ﬁdence assignment. The designers of the PharmGKB used this ap-
proach because they hypothesized that it would be capable of
coalescing the results of a range of methods and study types within
the ﬁeld of pharmacogenetics into a single data repository that
would be useful to all researchers in the ﬁeld [22].
2.2. Medical Subject Headings ‘‘publication types”
One of the most used biomedical evidence taxonomies is the
publication-type taxonomy that is a component of the Medical
Subject Headings (MeSH) controlled vocabulary [23]. The MeSH
controlled vocabulary is a set of over 20,000 terms used to index
a very broad spectrum of medical literature for the National Library
of Medicine’s PubMed database (formerly MEDLINE). Each article
in PubMed is manually indexed with several MeSH terms and addi-
tional descriptors including the article’s publication type. The
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classiﬁcation for the very wide range of articles indexed in Pub-
Med. Hence, the taxonomy is very broad but relatively shallow.
For example, publication types in the 2008 MeSH taxonomy [19]
include types as varied as Controlled Clinical Trial and
Sermons but only one type, In Vitro, that represents all kinds
of in vitro studies including those using non-human tissue.
In knowledge representation terms, the coverage by MeSH pub-
lication types of the evidence types relevant for validating drug-
mechanism knowledge is too coarse-grained. This is because the
design of some in vitro experiments makes them better suited for
supporting some drug-mechanism assertions more than others.
For example, a recent FDA guidance to industry on drug interaction
studies distinguishes three different in vitro experimental methods
for identifying which, if any, speciﬁc Cytochrome P-450 enzymes
metabolize a drug [15]. The three experiment types are different
from the in vitro experiment type that the FDA suggests is appro-
priate for identifying if a drug inhibits a drug metabolizing enzyme.
The next two sections will discuss two systems whose coverage of
in vitro evidence is less coarse than MeSH publication types—the
Gene Ontology evidence codes [20] and the Pathway Tools’ evi-
dence ontology [21].2.3. Gene Ontology ‘‘evidence codes” and the need for inclusion criteria
The Gene Ontology (GO) is a system of three separate ontologies
deﬁning relationships between biological objects in micro- and cel-
lular biology [24]. GO is a consortium-based effort that has gained
wide acceptance in the bioinformatics community because it sup-
ports consistent descriptions of the cellular location of a gene prod-
uct, the biological process it participates in, and its molecular
function. Authors of GO annotations are expected to specify an evi-
dence code that indicates how a particular annotation is supported.
GO evidence codes [20] are labels representing the kinds of support
that a biologist might use to annotate the molecular function, cel-
lular component, or biological process (s)he is assigning to a gene
or gene product. GO has over a dozen evidence codes including
codes that indicate that a biological inference is supported by
experimental evidence, computational analysis, traceable and
non-traceable author statements, or the curators’ judgement based
on other GO annotations.
In the DIKB, the user’s conﬁdence in an assertion rests on some
arrangement of one or more evidence types. This means that the
usermust trust the validity of each instance of evidence that the sys-
tem uses to meet the belief criteria without necessarily reviewing
the evidence for his or herself. In contrast with these requirements,
the authors of the GO evidence codes are very clear that the codes
cannot be used as a measure of the validity of a GO annotation:
Evidence codes are not statements of the quality of the annota-
tion. Within each evidence code classiﬁcation, some methods
produce annotations of higher conﬁdence or greater speciﬁcity
than other methods, in addition the way in which a technique
has been applied or interpreted in a paper will also affect the
quality of the resulting annotation [20].
This quote from GO evidence code documentation mentions
two possible characteristics of GO evidence codes that preclude
them from serving as a measure of the justiﬁcation for biological
annotations. First, GO evidence codes seem to represent evidence
types that vary in terms of their appropriateness for justifying
hypotheses. Like MeSH publication types, GO evidence codes are
too coarse-grained for use as a tool for conﬁdence assignment. Sec-
ond, GO evidence codes do not address the fact that there are many
possible problems with studies, experiments, author statements,
and other types of evidence that can effect their validity. In otherwords, even if GO evidence codes were granular enough for deci-
sion support, the user would have to assess the quality of each evi-
dence item directly or else place faith in the annotator’s judgment.
According to The Agency for Healthcare Research and Quality,
there are three components of a study that contribute or detract
from its quality—its design, how it is conducted, and how its re-
sults are analyzed ([25], p. 1). While it is possible to create meta-
data labels that accurately reﬂect a study’s design, it is intractable
to abstract the full range of issues that affect a study’s conduct and
analysis. Our approach to ensuring user conﬁdence in abstract evi-
dence types is to develop and consistently apply inclusion criteria
for each type of evidence in the DIKB. Inclusion criteria help ensure
that all evidence within a collection meet some minimum standard
in terms of quality. They are complimentary to evidence type def-
initions which should represent evidence classes that are fairly
homogeneous in terms of their appropriateness for justifying
hypotheses. The criteria are designed to help answer the kinds of
methodology questions that expert users have when told that an
evidence item is of a certain type.
2.4. The Pathway Tools’ ‘‘evidence ontology” and conﬁrmation bias
One other currently used biomedical evidence taxonomy is
found in the Pathway Tools system of pathway/genome databases
(PGDBs) [21]. The Pathway Tools evidence ontology is both a
computable evidence taxonomy and a set of data-structures de-
signed so that PGDB maintainers can attach (1) the types of evi-
dence that support an assertion in the PGDB, (2) the source of
each evidence item, and (3) a numerical representation of the de-
gree of conﬁdence a scientist has in an assertion. The taxonomy
component of the evidence ontology shares several of the types
deﬁned in GO evidence codes (Section 2.3) but adds a number of
sub-types that deﬁne more speciﬁc kinds of experiments and as-
says than GO. The data-structure component of the ‘‘evidence
ontology” enables PGDBmaintainers to record the source of an evi-
dence item, the accuracy of a given method for predicting speciﬁc
hypotheses, and the scientist’s conﬁdence in a PGDB assertion gi-
ven the full complement of evidence supporting an assertion.
PGDB users are presented with a visual summary of the kinds of
evidence support for a given assertion in the form of icons repre-
senting top-level evidence-types from the Pathway Tools’ evidence
taxonomy (e.g. ‘‘computational” or ‘‘experimental”). Users can click
on the icons to view more detailed information of the speciﬁc evi-
dence items represented by the top-level icons including the
sources of each item and its speciﬁc evidence type. This approach
enables Pathway Tools to provide an overview of the kinds of evi-
dence support for an assertion so that users might make their own
judgements on the amount of conﬁdence they should have in a
PGDB assertion.
While Pathway Tools’ evidence types serve a similar function as
DIKB evidence types by helping users assess their conﬁdence in
knowledge-base assertions, PGDB maintainers use them to repre-
sent only supporting evidence. We hypothesize that this approach
could contribute to a form of bias called conﬁrmation bias that
can undermine attempts by users of a knowledge-base to assess
the validity of its assertions.
Grifﬁn in his review of research in the domain probability judge-
ment calibration [26] lists several robust ﬁndings from a consider-
able body of research exploring biases people have when
estimating the likelihood of uncertain hypotheses. Among them
is the ﬁnding that people tend to exhibit various forms of over-con-
ﬁdence when estimating the probability that some hypothesis is
true. One possible explanation for this tendency is that over-conﬁ-
dence is a result of conﬁrmation bias—‘‘. . .people tend to search for
evidence that supports their chosen hypothesis” [26]. Under this
model, conﬁdence estimations should be more accurate when peo-
Fig. 1. The 16 drugs and 19 drug metabolites chosen for DIKB experiments.
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Grifﬁn reports that the results of some research studies are consis-
tent with this model but that conﬁrmation bias does not seem to
be the sole cause of over-conﬁdence during probability judgement.
We applied these results to the DIKB by requiring that main-
tainers seek both supporting and refuting evidence for each drug-
mechanism assertion. The intent of this arrangement is to help
maintainers avoid any tendency to collect evidence that only sup-
ports knowledge-base assertions and to help expert users create
unbiased criteria for judging their conﬁdence in the system’s
assertions.
2.5. Curator inferences and default assumptions
In both GO evidence codes and the Pathways Tools’ evidence
ontology there is an evidence type called Inferred by Curator
that curators use for knowledge they infer from other assertions or
annotations in the respective systems [20,21]. Inferred by Cura-
tor is not really an evidence type; rather it is a label indicating
that a particular assertion exists within a knowledge-base as a re-
sult of judgement of some curator. An evidence code of this type
will not work in the DIKB because its users must map their conﬁ-
dence in the system’s assertions to combinations of evidence
codes. A user viewing an assertion tagged with Inferred by
Curator might apply the level of trust that they have for the
knowledge source based on previous experiences. Unfortunately,
whatever judgement the user makes will be more about the
knowledge–curation system rather than the speciﬁc scientiﬁc
proposition in question. Alternatively, the expert might attempt
to explicitly trace the curators’ judgement so as to decide for them-
selves if the inference was reasonable. This process might be
straightforward or confusing depending on the complexity of the
logic used by the curator when making the inference in question.
In constructing the DIKB we have also found situations where it
was desirable to assert some knowledge element based on our
knowledge of other assertions in the system. As a trivial example,
when evidence in the DIKB supports the assertion that some en-
zyme, E, is responsible for 50% or more of some drug or drug
metabolite’s total clearance from the body, then the system should
also contain an assertion that more than 50% of a drug’s clearance
is by metabolism. A more complex example can be found in the
rules that the DIKB uses to infer a drug or drug metabolite’s
metabolic clearance pathway (Appendix E, supplementary mate-
rial). In such cases, new rules are added to the DIKB so that it will
automatically add the needed assertions to its knowledge-base.
The system’s links each automatically-inferred assertion to the
assertions and rules from which it was inferred. A programmer
can write code that leverages the data structures used to create
the DIKB’s evidence-base to generate a report showing the logic
and evidence support for any automatically-inferred assertions.1
The advantage of the DIKB’s approach becomes apparent when
one considers that the construction and maintenance of a large
knowledge-base is a collaborative effort. GO and the PGDBs in
the Pathway Tools system require curation by many domain ex-
perts and we think it reasonable to expect that, in spite of the best
of intentions, curators will sometimes make mistakes or not be en-
tirely consistent in how they enter knowledge or assign evidence.
Furthermore, as a knowledge-based system grows it becomes less
tractable for curators to know all of the inferences supported di-
rectly by other knowledge in the system. In contrast, once a rule
is added to the DIKB that makes an assertion based on other asser-1 More speciﬁcally, the DIKB uses declarative rules and Truth Maintenance System
(TMS) justiﬁcations to automatically add the needed assertions to knowledge-base
[17]. The system’s TMS links each automatically inferred assertion to the assertions
and rules from which it was inferred.tions present in the system, it will always be applied consistently
and across all possible instances where it is applicable.
It turns out that there are other occasions where an evidence
type like Inferred by Curator might seem applicable within
the DIKB. The system’s curators sometimes face situations where
they are justiﬁed in entering an assertion without linking it to evi-
dence. Such an event can occur when the curator is unable to ﬁnd
evidence for an assertion or when (s)he decides that an assertion
does not need to be justiﬁed by evidence. In both cases the DIKB
curator can decide to enter it as a default assumption. A default
assumptions is a special kind of assertion considered justiﬁed by
default but retractable either manually by curators or automati-
cally by the system as it proceeds with inference.
2.6. Summary of considerations
In summary, none of the evidence taxonomies that we reviewed
have sufﬁcient coverage of all the kinds of evidence that might be
relevant for representing drug mechanism knowledge. Also, none
are designed so that users can assess their conﬁdence in each type
either by itself or in combination with other types. The next section
discusses the new evidence taxonomy that meets these
requirements.
3. The DIKB evidence taxonomy and inclusion criteria
The current DIKB evidence taxonomy (shown in Table 3) con-
tains 36 evidence types arranged under seven groupings represent-
ing evidence from retrospective studies, clinical trials, metabolic
inhibition identiﬁcation, metabolic catalysis identiﬁcation, state-
ments, reviews, and observational reports.
We developed the taxonomy iteratively by collecting evidence
for the drugs and drug metabolites shown in Fig. 1, identifying
the attributes of each evidence item, and deciding on evidence-
type deﬁnitions. We were able to incorporate some deﬁnitions
from WordNet [27], MeSH [23], and NCI Thesaurus [28] but the
majority of the taxonomy consists of new deﬁnitions. The structure
of the taxonomy and granularity of its deﬁnitions is similar to the
Pathway Tools’ evidence ontology [21] though the only deﬁnitions
that the two resources share are for traceable and non-traceable
author statements. Also, we deliberately excluded the ‘‘Inferred
by Curator” evidence type present in the Pathway Tools’ evidence
ontology [21] and Gene Ontology’s evidence codes [20] for the rea-
sons discussed in Section 2.5.
We implemented the taxonomy in the OWL-DL language [29]; a
description logic that provides a formal semantics for representing
taxonomic relationships in a manner that can be automatically
checked to ensure consistent classiﬁcation. We used the Protégé
ontology editor2 to create the taxonomy and the RACER inference
engine [30] to test it for consistent type deﬁnitions. The evidence2 http://protege.stanford.edu/.
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and is available on the Web [31].
We designed the set of seven inclusion criteria shown in Appen-
dix B (supplementary material) to compliment a sub-set of evi-
dence type deﬁnitions from the DIKB’s evidence taxonomy. Like
the evidence taxonomy, we developed the inclusion criteria itera-
tively during the early stages of collecting evidence for the drugs
and drug metabolites shown in Fig. 1. This meant that changes to
inclusion criteria would sometimes require that evidence previ-
ously thought acceptable be discarded. The criteria became stable
after making progress collecting evidence on several drugs. In their
current form, the seven criteria deﬁne the minimum quality stan-
dards for 21 evidence types in the taxonomy.
There were a total of 12 evidence types for which we did not de-
ﬁne inclusion criteria. Seven of these are general evidence types:
Statement, Non-traceable Statement, An observation-based report,
An observation-based ADE report, A clinical trial, A DDI clinical trial,
and A retrospective study. We used more speciﬁc evidence types
within the taxonomic sub-hierarchies that these ﬁve types resided
in and so deﬁned inclusion criteria accordingly.
The other ﬁve evidence types with no inclusion criteria repre-
sent classes of evidence that we decided not to include for this
study. We excluded the two types of author statements in the tax-
onomy (A traceable author statement and A traceable drug-label
statement) because our evidence collection policy requires that
curators retrieve and evaluate the evidence source that an author’s
statement refers to rather than rely strictly on the author’s inter-
pretation of that evidence source. We excluded the type A retro-
spective population pharmacokinetic study because we thought
evidence of this class would be difﬁcult to acquire and interpret.
We also neglected to deﬁne inclusion criteria for the type A retro-
spective DDI study because we did not come across evidence of this
type while deﬁning inclusion criteria. Finally, the evidence collec-
tion process that we describe in Section 4.1 did not include public
adverse-event reporting databases so we did not deﬁne inclusion
criteria for the type An observation-based adverse-drug event report
in a public reporting database.3 The professional role of each co-investigator during the evidence collection
process is mentioned throughout this section to convey to the reader the interdis-
ciplinary approach used to construct the evidence base.
4 http://www.druginteractioninfo.org/.4. Using the DIKB’s evidence taxonomy to represent a body of
drug-mechanism evidence
We applied the novel evidence taxonomy to the task of repre-
senting drug-mechanism evidence for six members of a family of
drugs called HMG-CoA reductase inhibitors (statins) and ten drugs
with which they are sometimes co-prescribed. Members of the sta-
tin drug family are very commonly used to help treat dyslipidemia.
While statins have a relatively wide therapeutic range, patients
taking a drug from this class are at a higher risk for a muscle dis-
order called myopathy if they take another drug that reduces the
statin’s clearance [32]. The 16 drugs we chose are all currently sold
on the US market, popularly prescribed by physicians, and have
been the subject of numerous in vivo and in vitro pharmacokinetic
studies. Many of them are known to be cleared, at least partly, by
drug metabolizing enzymes that are susceptible to inhibition.
DDIs that occur by metabolic inhibition can affect the concen-
tration of active or toxic drug metabolites in clinically relevant
ways. For example, both lovastatin and simvastatin are adminis-
tered in lactone forms that have little or no HMG-CoA reductase
inhibition activity but that are readily converted by the body to
pharmacodynamically active metabolites [33,34]. Clinical trial data
indicates that metabolism by CYP3A4 is a clinically relevant clear-
ance pathway for these metabolites [35,36]. Similarly, in vitro evi-
dence indicates that CYP3A4 is the primary catalyst for the
conversion of the HMG-CoA reductase inhibitor atorvastatin into
its two active metabolites [37]. For this reason, we also collectedand entered drug-mechanism evidence for 19 active metabolites
of the drugs we had chosen. Fig. 1 lists the 16 drugs and 19 drug
metabolites we chose to represent in the DIKB.
4.1. The evidence collection process
The quality and coverage of the DIKB’s drug-mechanism knowl-
edge depends a great deal on the process used to collect and main-
tain evidence. We attempted to apply a process geared toward
building a coherent body of knowledge that has minimal bias
and is up-to-date. One informaticist (RB) and two drug-experts
(CC and JH) formed an evidence board that was responsible for
collecting and entering all evidence into the DIKB.3 The evidence-
collection process was iterative for the ﬁrst few months while
evidence types and inclusion criteria were being developed. The board
would choose a particular drug to model then collect a set of journal
articles, drug labels, and authoritative statements that seemed
relevant to each of the various drug-mechanism assertions in the
DIKB’s rule-based theory of drug-drug interactions. The evidence
board would then meet together and discuss each evidence item and
the issues that affected its use in the DIKB. By the time all members
of the evidence board committed to using the evidence types (Table 3)
and inclusion criteria (Appendix B, supplementary material) the
following evidence collection process had become routine:
(1) The evidence board chose a particular drug to model.
(2) The informaticist then received from each drug expert refer-
ences to speciﬁc evidence sources that they thought would
support or rebut one or more drug-mechanism assertions.
(3) The informaticist did his own search of the literature that
included seeking information from primary research articles
in PubMed, statements in drug product labeling or FDA guid-
ances, and various drug information references including
Goodman & Gilman’s [38]. One of the drug experts was afﬁl-
iated with the proprietary University of Washington Metabo-
lism and Transport Drug Interaction Database4 and performed
searches of that resource then forwarded the results to the
informaticist.
(4) The informaticist would then summarize all evidence items
from each source, classify their evidence types, and check if
they met inclusion criteria. The evidence board would then
meet and decide as a group whether each evidence item
should enter the DIKB’s evidence-base or be rejected as sup-
port or rebuttal for a speciﬁc assertion.
(5) The informaticist would enter accepted evidence items into
the DIKB using the DIKB’s Web interface. He also entered
rejected evidence items into a simple database used by the
DIKB during evidence validation tests.
The DIKB performed several validation tests on each new evi-
dence entry before it was stored in the system’s evidence-base.
These included checking if an evidence entry was redundant or
had previously been rejected by DIKB curators as support or rebut-
tal for the assertion it was being linked to. The system also checked
if a new evidence item would create an evidence pattern that was
indicative of circular reasoning by evidence-base curators. This last
test was possible because we made sure to explicitly represent any
conjectures behind a speciﬁc application of evidence. The next sec-
tion describes the motivation for representing conjectures and the
novel algorithm used to identify circular reasoning.
Fig. 2. A circular line of evidence support that indicates circular reasoning within
the evidence-base.
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Interpreting the results of a scientiﬁc investigation as support
for a particular assertion can sometimes require making conjec-
tures that scientiﬁc advance might later prove to be invalid. If such
conjectures are later shown to be false, it is important to re-con-
sider how much support the scientiﬁc investigation lends to any
assertion it was once thought to support. One unique feature of
the DIKB is that it can represent the conjectures behind a speciﬁc
application of evidence. These representations are called evi-
dence-use assumptions and they facilitate keeping knowledge in
the system both current and consistent.
4.2.1. Evidence-use assumptions help keep knowledge current
To illustrate how evidence-use assumptions help keep knowl-
edge current suppose that a pharmacokinetic clinical trial involv-
ing healthy patients ﬁnds a signiﬁcant increase in the systemic
concentration of drug-A in the presence of drug-B. If the study
meets inclusion criteria, and it is thought that drug-B is a selective
inhibitor of the ENZ enzyme in humans, then an evidence-base
curator might apply this evidence as support for the assertion
(drug-A substrate-of ENZ). This particular application of the
hypothetical study would depend on the conjecture that drug-B
is an in vivo selective inhibitor of the ENZ. Otherwise, alternative
explanations for the observed increase in the systemic concentra-
tion of drug-A remain quite feasible. In this situation, it will be
important to reconsider this use of evidence if future work reveals
that drug-B increases patient exposure to drug-A by some other
mechanism than reducing ENZ’s catalytic function (such as modu-
lation of the function of an alternate drug-metabolizing enzyme or
an efﬂux transport protein).
Unlike systems that just cite evidence, the DIKB’s formal model
of evidence enables it to ﬂag when a conjecture has become invalid
and alert knowledge-base curators to the need to reassess their ori-
ginal interpretation of what assertions a piece of evidence sup-
ports. Currently, DIKB curators make an evidence-use assumption
known to the DIKB by ﬁrst identifying the label of an assertion in
the knowledge-base that represents the evidence-use assumption.
They then add the label to a list of assumptions that is contained in
the data structure used to represent the speciﬁc evidence item that
they are viewing.
In our experience, evidence-use assumptions are an attribute
of a particular type of evidence. For example, pharmacokinetic
DDI studies, like the one mentioned in the previous hypothetical
example, often depend on the assumption that the precipitant
has no measurable effect on any other clearance route of the
object drug. This is an evidence-use assumption that applies to
all pharmacokinetic drug–drug interaction studies using selec-
tive inhibitors. Based on this observation, we have attempted
to deﬁne evidence-use assumptions for each new evidence type
that is added to the DIKB’s evidence taxonomy. These assump-
tions are written as general statements that apply to one or
more evidence types and are added to inclusion criteria docu-
mentation so that curators will know what speciﬁc assump-
tion(s) to declare when adding an item of evidence to the
system. After curators have approved an evidence item, they
identify assertions within the DIKB that match each speciﬁc evi-
dence-use assumption. In many cases, a suitable assertion will
not be present in the DIKB. If so, curators must add the new
assertion to the DIKB then link it as an evidence-use assumption
for the evidence item.
4.2.2. Evidence-use assumptions help keep knowledge consistent
Evidence-use assumptions can also help identify a pattern, called
a circular line of evidence support, that is indicative of fallacious rea-
soning by evidence-base curators. A hypothetical example shouldhelp clarify the kind of situation we are describing and its
implications.
Assume some evidence item, E, exists in the evidence-base as
support for the assertion (drug-B inhibits ENZ) and that
(drug-A primary-clearance-enzyme ENZ) is an evidence-
use assumption for this application of E. In addition, assume that
E also acts as support for (drug-A primary-clearance-en-
zyme ENZ) and that this other use of E depends on the validity
of the assertion (drug-B inhibits ENZ). If there is no evidence
against either assertion and E meets both assertions’ supporting
belief criteria, then the system will consider both assertions to
be valid.
Fig. 2 makes apparent the dilemma—the conjecture, (drug-A
primary-clearance-enzyme ENZ), is necessary for evidence
item E to act as support for the assertion (drug-B inhibits
ENZ) but is being justiﬁed by the same evidence item, E, that as-
sumes the same proposition E is supposed to justify. Intriguingly,
the same unsound reasoning would be present even if evidence
item E is being used to refute the assertion (drug-B inhibits
ENZ). Neither kind of circular reasoning should be allowed in the
DIKB’s evidence-base.
We have designed and implemented the following algorithm in
the DIKB for detecting when an new evidence item would cause a
circular line of evidence support:
Let E be an evidence item that is being considered as evidence
for or against some assertion, A. Assume that the use of E as evi-
dence for or against A is contingent on the validity of one or
more other assertions in the set AL ¼ as1; as2; . . . ; asn. The set
of assertions in AL are the evidence-use assumptions for E. If E
is currently being used as evidence for or against some asser-
tion, asi, in AL and the use of E to support or refute asi depends
on assuming A, then the use of E to support or refute A would
create a circular line of evidence support.
The DIKB will not allow a curator to enter an evidence item that
passes this test into its evidence base.
Circular reasoning might be present in the evidence-base any-
time an evidence-use assumption is supported by the same evidence
item that the assumption is linked to. We can create an algorithm
to identify when this form of circular evidence support is present
in the knowledge-base by simplifying the previous algorithm.
Let E be an evidence item and let the set AL ¼ as1; as2; . . . ; asn be
the set of evidence-use assumptions for E. If E is currently being
used as evidence for or against some assertion, asi, in AL, then
circular reasoning might be present in the evidence-base.
The DIKB does not currently implement this algorithm in its val-
idation tests but will in future versions.
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Work on the evidence-base stopped in January 2008. In its
present state it consists of 257 evidence items from 102 unique
sources applied as evidence for or against 207 drug-mechanism
assertions.
5.1. The classiﬁcation of evidence within the evidence-base
The evidence board used only one-third of the 36 types in the
evidence taxonomy to classify all the 257 evidence items. Some
evidence types were not used because of speciﬁc evidence collec-
tion policies while other types were not used because no accept-
able evidence in their class could be found. For example, even
though the evidence board collected numerous case reports
describing adverse drug events in patients taking two or more of
the drugs in our study, none of the ﬁve observation-based evidence
types were entered into the system. This was because none of the
reports that were found measured the systemic concentrations of
the purported object drug in a way that satisﬁed the inclusion cri-
teria for supporting or refuting an assertion about a drug’s meta-
bolic properties.
The 12 evidence types that were used to classify evidence items
are shown in Table 1 along with the number of supporting or refut-
ing evidence items each type was assigned to. It is clear from Table
1 that some evidence types are present in the evidence-base much
more often than other types even though the experiments they
represent have relatively similar purposes. For example, the evi-
dence-base has almost eightfold more evidence items of the type
A CYP450, human microsome, metabolic enzyme inhibition experi-
ment then the type A CYP450, recombinant, metabolic enzyme inhibi-
tion experiment even though the purpose of both kinds of
experiments is to test a drug or drug metabolite’s ability to inhibit
some enzyme in vitro. Similarly, the system has three-fold more
items of the type A CYP450, recombinant, drug metabolism identiﬁca-
tion experiment with possibly NO probe enzyme inhibitor(s) than the
type A CYP450, human microsome, drug metabolism identiﬁcation
experiment using chemical inhibitors even though both experiments
attempt to identify the CYP450 enzymes capable of metabolizing a
drug or drug metabolite in vitro.
Generally deﬁned evidence types were often used when an
evidence item did not ﬁt one of the more speciﬁc evidence-Table 1
The evidence board used only one-third of the 36 types in the evidence taxonomy to classi
table along with the number of supporting or refuting evidence items each type was assig
Evidence type
Clinical trial types
A pharmacokinetic clinical trial
A genotyped pharmacokinetic clinical trial
A randomized DDI clinical trial
A non-randomized DDI clinical trial
A parallel groups DDI clinical trial
Total
In vitro experiment types
A CYP450, recombinant, metabolic enzyme inhibition experiment
A CYP450, human microsome, metabolic enzyme inhibition experiment
A drug metabolism identiﬁcation experiment
A CYP450, recombinant, drug metabolism identiﬁcation experiment with possibly NO
A CYP450, human microsome, drug metabolism identiﬁcation experiment using chem
Total
Non-traceable statement types
A non-traceable, but possibly authoritative, statement
A non-traceable drug-label statement
Totaltypes within a particular sub-hierarchy. Eleven of the 12 types
shown in Table 1 are sub-types of some other, more general,
evidence types within the greater evidence taxonomy. One
exception was the most general in vitro evidence type A drug
metabolism identiﬁcation experiment that is assigned four times
in the current DIKB evidence-base. All four uses of the evidence
type were to classify metabolite identiﬁcation experiments that
could not be classiﬁed using the more speciﬁc types within the
hierarchy.
5.2. Observed biases
One can calculate from Table 1 that evidence types assign-
ments in the current DIKB slightly favor clinical trial types
(42%) over in vitro studies (27%) and non-traceable statements
in drug labeling and FDA guidance documents (30%). The dis-
tribution of evidence types among individual assertion types is
much more diverse than that of the evidence-base as a whole
(Tables 3 and 4 in supplementary material). For example, all
15 evidence items linked to inhibition-constant assertions
are from in vitro evidence types while no in vitro evidence is
currently linked to a maximum-concentration assertion.
Likewise, two-thirds of the evidence items linked to maxi-
mum-concentration assertions are instances of clinical trial
types while the one-third are instances of non-traceable state-
ment types. Approximately the opposite distribution of evi-
dence types is present in items linked to bioavailability
assertions (38% clinical trial types and 62% non-traceable
statements).
While the evidence board attempted, where appropriate, to col-
lect both supporting and refuting evidence for each assertion, the
current evidence-base is strongly biased toward supporting evi-
dence. Eighty-two percent of the 102 evidence sources provide evi-
dence items that are used strictly as support for one or more
assertions. In comparison, only 3% of sources provide strictly refut-
ing evidence items and only 15% of sources provide both support-
ing and refuting evidence items. Of the 257 non-redundant
evidence items, 229 (89%) support, and 28 (11%) refute, some drug
mechanism assertion. In terms of the 20 assertions types that the
DIKB currently represents, only four (20%) have any assertions with
refuting evidence; substrate-of, inhibits, increases-auc,
and primary-metabolic-enzyme.fy all the 257 non-redundant evidence items. The 12 evidence types are shown in this
ned to. Indented evidence types are sub-types of the type in the previous row.
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A sample of ﬁve of the 58 evidence items in the DIKB’s evidence-base that were entered with evidence-use assumptions.
Source Assertion evidence is supporting Evidence type Evidence-use assumption(s)
[45] Diltiazem inhibits CYP3A4 A randomized DDI clinical trial Triazolam’s primary-total-clearance enzyme is CYP3A4
[36] Simvastatin is a substrate-of
CYP3A4
A randomized DDI clinical trial Itraconazole is a selective inhibitor of CYP3A4 in vivo
[46] Alprazolam is a substrate-of
CYP3A5
A genotyped pharmacokinetic clinical trial CYP3A5 has multiple drug-metabolizing phenotypes
[47] Clarithromycin is a substrate-of
CYP3A4
A CYP450, human microsome, drug metabolism identiﬁcation
experiment using chemical inhibitors
Ketoconazole is a selective inhibitor of CYP3A4 in vitro
[35] Lovastatin’s primary-total-
clearance enzyme is CYP3A4
A randomized DDI clinical trial (1) Itraconazole’s sole PK effect (in this study) is to alter
the metabolic clearance lovastatin
(2) Itraconazole is a selective inhibitor of CYP3A4 in vivo
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The evidence-board labeled approximately one-ﬁfth (39) of the
assertions in the DIKB default assumptions. Nearly half (17) of the
default assumptions were entered because of a DIKB policy that
treated certain information in FDA guidances as completely
authoritative.5 The 17 assertions are linked to evidence items that
refer to the FDA guidance that prompted the evidence-board’s deci-
sion to make them default assumptions.
Another 17 assertions are labeled default assumptions but have
no evidence items linked to them at all. Five of these were entered
by the evidence board because of actions speciﬁed in the inclusion
criteria for pharmacokinetic DDI studies (deﬁned in Appendix B of
supplementary material). The remaining 12 were entered without
evidence based on the knowledge of one or more members of the
evidence-board. These were entered as default assumptions out of
convenience with the intent that a DIKB curator would seek evi-
dence for and against the assertions at a later time.
5.4. The application of evidence-use assumptions
Nearly one-quarter (23%) of the evidence items in the current
evidence-base have at least one evidence-use assumption. Table 2
provides a sample of ﬁve of these evidence items. Fifty-three evi-
dence items are linked to one evidence-use assumption and ﬁve evi-
dence items are linked to two bringing the total number of
evidence-use assumptions in the current DIKB to 63. Only 23 (11%)
of the 207 assertions in the DIKB comprise all 63 evidence-use
assumptions. The number of times the evidence board used any
speciﬁc assertion as an evidence-use assumption ranged from once
to nine times (mean: 2.7, median: 1.0).
6. Discussion and conclusion
We successfully used the DIKB’s new evidence taxonomy to
integrate drug mechanism evidence from a variety of sources
including in vitro experiments, clinical trials, and statements from
drug product labels. The evidence taxonomy and related inclusion
criteria were instrumental to ensuring that the evidence entered
into the DIKB was of high quality. All 257 evidence items in the
DIKB are labeled by their type from the novel evidence taxonomy
and meet the inclusion criteria for their assigned type. The taxon-
omy was also used extensively in a set of tests used to ensure that
the current evidence-base has no redundant entries, rejected evi-
dence items, or applications of evidence that were the result of cir-
cular reasoning by the co-investigators.5 Speciﬁcally, DIKB curators assumed the validity of drugs or chemicals listed as
selective inhibitors or probe substrates of certain drug-metabolizing enzymes in an
FDA guidance to industry on drug-interaction studies [15].6.1. Limitations of the current evidence-base
The DIKB is designed so that expert users can deﬁne belief cri-
teria using abstract evidence types. Incorrect classiﬁcation of an
evidence item’s type could cause the system to falsely appear as
if it has satisﬁed the user’s belief criteria. One limitation of the cur-
rent evidence-base is that we did not independently evaluate how
accurately and consistently the evidence-board classiﬁed evidence.
The evidence board employed some internal consistency checks
such as reviewing each evidence item multiple times before it
was entered into the DIKB and using double-entry methods to
track an evidence item’s progress through the evidence collection
process. However, it would be desirable to acquire independent
veriﬁcation that the evidence-board’s classiﬁcations were accurate
and consistent across all entries.
While the evidence board attempted to collect both supporting
and refuting evidence for each assertion, the current evidence-base
is strongly biased toward supporting evidence (see Section 5.2). It
is possible that this bias in the DIKB’s evidence-base is a reﬂection
of a more general bias in the scientiﬁc literature towards publish-
ing studies that conﬁrm hypotheses. Our methods are not capable
of answering this question deﬁnitively because we do not claim to
have collected an exhaustive set of evidence within any of our evi-
dence classiﬁcations. It is unclear at this time if this observed bias
will hinder the system’s ability to help users overcome any ten-
dency toward conﬁrmation bias (see Section 2.4).
Another limitation of the current evidence-base is that the evi-
dence-board did not search for evidence in the FDA Summary Basis
for Approval for each drug or the EMBASE,6 Web of Science, Coch-
rane Library,7 or CINHAL8 publication databases. It is possible that
these resources might contain important evidence that is now miss-
ing in the DIKB. Future work on the evidence-base should include
comprehensive searches of these sources as well as other possible
sources such as The Medical Letter.9
6.2. Future work on the taxonomy
While the taxonomy provides coverage of a broad range of pos-
sible evidence types relevant for support drug mechanism asser-
tions, it is likely that many other evidence types are yet to be
deﬁned and included. Most evidence items in the DIKB (98%) are
classiﬁed using relatively speciﬁc types within the taxonomy.
However, as Section 5.1 notes, there is a need for additional types
to more speciﬁcally classify metabolite identiﬁcation experiments.
Future work will address this need and the need for a detailed eval-
uation of the taxonomy to test its coverage and determine if there





The version of the DIKB’s evidence taxonomy used in the reported study.
[EV_Clinical_Trial] A clinical trial: ‘‘a pre-planned clinical study of the safety, efﬁcacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or
prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predeﬁned evidence of favorable
and unfavorable effects.” - (Medical Subject Headings (MeSH) [23] version 2008, concept code D016430, Clinical Trial)
[EV_CT_DDI] A DDI clinical trial: A study designed to quantify the pharmacokinetic and/or pharmacodynamic effects within study participants of a single drug in the
presence of a purported precipitant
[EV_PK_DDI_NR] A non-randomized DDI clinical trial: A pharmacokinetic DDI study where participants receive a drug in the presence of a purported precipitant
(experimental group) or not (control group) but participants are not randomly assigned to experiment and control groups. This can include ﬁxed-order studies
where all participants are tested with placebo and precipitant after some period of washout
– [EV_PK_DDI_Par_Grps] A parallel groups DDI clinical trial: A pharmacokinetic DDI study involving two groups of non-randomized participants where both
groups receive the purported object drug while only one group receives the purported precipitant
[EV_PK_DDI_RCT] A randomized DDI clinical trial: A randomized, controlled, pharmacokinetic DDI study where participants receive a drug either in the presence of
a purported precipitant (experimental group) or not (control group)
[EV_CT_Pharmacokinetic] A pharmacokinetic clinical trial:”A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the
body.” (NCI Thesaurus [28] version 8, concept code C49663, Pharmacokinetic Study)
– [EV_CT_PK_Genotype] A genotyped pharmacokinetic clinical trial: A drug pharmacokinetics study whose population consists of at least two groups known to
posses distinct forms of some drug-metabolizing enzyme
– [EV_CT_PK_Phenotype] A phenotyped pharmacokinetic clinical trial: A drug pharmacokinetics study whose population consists of at least two groups known
to posses distinct drug metabolizing phenotypes
[EV_Retrospective] A retrospective study:”Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived
from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study
have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.” (Medical Subject Headings (MeSH) [23] version
2008, concept code D012189, Retrospective Studies)
– [EV_PK_DDI_Retro] A retrospective DDI study: A retrospective studylooking at the change in patient exposure of a single drug in the presence of a purported
precipitant using a retrospective set of clinical records
– [EV_Population_PK] A retrospective population PK study: a ‘‘...study of the sources and correlates of variability in drug concentrations among individuals who
are the target patient population receiving clinically relevant doses of a drug in question.” ([48], p.1)
[EV_EX_Met_Enz_ID] A drug metabolism identiﬁcation experiment: An experiment conducted with biological tissues and/or chemical compounds in a laboratory
designed to identify the speciﬁc enzymes responsible for the metabolism of a drug ([15], p. 25)
[EV_EX_Met_Enz_ID_Cyp450] A CYP450 drug metabolism identiﬁcation experiment: A metabolic enzyme identiﬁcation experiment speciﬁcally designed to identify
the Cytochrome P-450 enzymes involved in the metabolism of a drug
[EV_EX_Met_Enz_ID_Cyp450_Hum_Recom] A CYP450, recombinant, drug metabolism identiﬁcation experiment with possibly NO probe enzyme inhibitor(s)
– [EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Chem] A CYP450, recombinant, drug metabolism identiﬁcation experiment using chemical inhibitors
– [EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Antibody] A CYP450, recombinant, drug metabolism identiﬁcation experiment using antibody inhibitors
[EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome] A CYP450, human microsome, drug metabolism identiﬁcation experiment: A Cytochrome P-450 metabolic enzyme
identiﬁcation experiment using human liver microsomes that have been characterized for Cytochrome P-450 activity and possibly NO probe enzyme inhibitor(s)
– [EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem] A CYP450, human microsome, drug metabolism identiﬁcation experiment using chemical inhibitors
– [EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Antibody] A CYP450, human microsome, drug metabolism identiﬁcation experiment using antibody inhibitors:
[EV_EX_Met_Enz_Inhibit] A metabolic enzyme inhibition experiment: An experiment conducted with biological tissues and/or chemical compounds in a laboratory
designed to determine whether or not a drug inhibits a speciﬁc drug-metabolizing enzyme
[EV_EX_Met_Enz_Inhibit_Cyp450] A CYP450 metabolic enzyme inhibition experiment: A metabolic inhibition experiment speciﬁcally designed to determine
whether or not a drug inhibits a speciﬁc CYP450 enzyme
[EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Recom] A CYP450, recombinant, metabolic enzyme inhibition experiment: A Cytochrome P-450 inhibition experiment
using recombinant human enzymes
– [EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome] A CYP450, human microsome, metabolic enzyme inhibition experiment: A Cytochrome P-450 metabolic
enzyme inhibition experiment using human liver microsomes that have been characterized for Cytochrome P-450 activity
[EV_Observation] An observation-based report: An observation-based report of some occurrence
[EV_Obs_ADE] An observation-based ADE report: An observation-based report of an adverse drug event
– [EV_Obs_ADE_Public_Reported] An observation-based ADE report in a public reporting database: An adverse event report on ﬁle in a public adverse event
reporting database such as the FDA’s Adverse Event Reporting System
[EV_Obs_DI_CR] A published observation-based ADE report: An published observation-based case-report of a drug interaction
– [EV_Obs_DI_CR_Evaluated] A published and evaluated observation-based ADE report: An observation-based report of a drug interaction that has been eval-
uated by some assessment tool
[EV_Review] A review article: A published analysis of the evidence supporting and/or refuting some topic
[EV_Drug_Review] A drug review article: A published analysis of research on the efﬁcacy or safety of a drug, family of drugs, or drug therapy.
– [EV_DrugClinicalReview] An FDA clinical review: An FDA-sponsored review of a drug’s pre-market studies and adverse event reports.
[Statement] A statement: A published artifact that is ‘‘. . .the basis for belief or disbelief; knowledge on which to base belief” see the term ‘‘evidence” in Wordnet
version 3.0 [27]
[Non_Traceable_Statement] A non-traceable, but possibly authoritative, statement: A statement that does not explicitly refer to evidence items in justiﬁcation of
its assertion(s) or that refers to an evidence item that is not accessible to the curator (e.g. pre-market drug studies only accessible to drug-company or FDA
researchers)
– [Non_traceable_Drug_Label_Statement] A non-traceable drug-label statement: An assertion found in a drug label that does not provide any traceable cita-
tions for its evidence support
[Traceable_Statement] A traceable statement: A statement that provides citation to evidence support for justiﬁcation of its assertion(s)
– [Traceable_Drug_Label_Statement] A traceable drug-label statement: An assertion stated in a drug label that provides citations for its evidence support
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hypotheses that (1) expert users should be able to assess their con-ﬁdence in the system’s assertions relatively quickly once they are
familiar with evidence type deﬁnitions and their associated inclu-
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be more consistent than requiring the expert to review the original
sources for each evidence item.
6.3. Future work to support evidence collection
Some assertions in the evidence-base have numerous pieces of
evidence to support them of many different types. For example, as
of this writing, the assertion (itraconazole inhibits CYP3A4)
can be supported by at least three randomized clinical trials [39–
41], drug product labeling [42], and an FDA guidance [15]. An inter-
esting question in this case is—when should one stop collecting
evidence for an assertion?
DIKB curators are charged with collecting a minimally biased
body of relevant evidence from which customized views of drug-
mechanism knowledge can be created. Since the belief criteria of
different expert users will not necessarily be known in advance,
curators must attempt to collect all available items of each evi-
dence type that is relevant for supporting or refuting each asser-
tion. The evidence collection approach that we used (Section 4.1)
went a long way toward achieving this ideal. However, time con-
straints and an over-abundance of evidence for some assertions,
meant that we did not collect all relevant evidence items of each
evidence type. Achieving the ideal will certainly require the use
of advanced informatics tools to ease the curators task. Research
in machine learning and artiﬁcial intelligence provides several
examples of machine classiﬁers that accurately identify relevant
articles from indexed research abstracts [43] and automatically ex-
tract biomedical relationships [44]. We think that human curators
should always make the ﬁnal decision as to how to apply a given
item of evidence but automated tools have the potential to greatly
ease their task.
6.4. Conclusion
We have presented a novel drug-mechanism evidence taxon-
omy that, when combined with a set of inclusion criteria, enables
drug experts to specify what their conﬁdence in a drug mechanism
assertion would be if it were supported by a speciﬁc set of evi-
dence. While it is likely that many other evidence types are yet
to be deﬁned and included in the taxonomy, the current version
was instrumental to ensuring that the 257 drug-mechanism evi-
dence items entered into the DIKB’s current evidence-base were
of high quality.
We have also highlighted features of the evidential knowledge-
representation approach implemented in the DIKB that should be
useful for representing knowledge in other biomedical domains
where knowledge is dynamic, sometimes missing, and often uncer-
tain. Rather than provide expert users with a static view of knowl-
edge within a speciﬁc domain, the evidential approach enables
them to construct customized views of a comprehensive body of
knowledge based on their own, subjective, interpretation of evi-
dence. An even more powerful feature of an evidential system is
that it can iterate through a large number of possible evidence-
type combinations to determine which combination of evidence
enables a model or theory to make the most optimal set of predic-
tions in terms of accuracy and coverage of a validation set. Part II of
this series provides a complete description an experiment we con-
ducted to explore if this the method could be used to make accu-
rate and clinically relevant DDI predictions.
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